Caruso I, Cignarelli A, Sorice GP, Natalicchio A, Perrini S, Laviola L, et al
Understanding the pharmacological profiles of both medication classes is essential for safe and effective management of patients requiring combination therapy for their metabolic and cardiovascular conditions
These patients are at a greater risk of major cardiovascular events such as stroke, heart attack, or death
In November 2022, Biocon Limited, an innovation-driven global biopharmaceutical company, signed a semi-exclusive partnership agreement with Zentiva, a leading European pharmaceutical company, to commercialize Liraglutide, a vertically integrated, complex formulation for the treatment and management of Type 2 diabetes and obesity
Cause significant weight loss (15-25% of body weight)
Working solutions of GEP44, GEP12, Ex-4, or vehicle control were administered by subcutaneous injection once daily at the start of the dark cycle using a 1 cc 29G insulin syringe